CareDx announced the publication of data demonstrating the clinical utility of measuring AlloSure in repeat kidney transplant recipients in the American Journal of Transplantation. AlloSure is the first donor-derived cell-free DNA test to assess allograft health and is broadly available to transplant patients. Previous publications demonstrating the clinical value of AlloSure were based on first-time or single kidney transplant recipients, or SKTR; the current study is the first study to include repeat kidney transplant recipients, or RKTR. In patients without evidence of rejection, the median readouts of AlloSure were significantly lower than threshold levels for rejection in both SKTR and RKTR. In patients with active rejection, AlloSure levels were similarly elevated in SKTR and RKTR patients alike.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.